Breakthrough Injection Discovered for treatment of Geographic Atrophy
SYFOVRE™ (pegcetacoplan injection), a medication that treats geographic atrophy (GA) brought on by age-related macular degeneration, has received approval from the U.S. Food and Drug Administration. (AMD).
It is the first and only treatment for GA to receive FDA clearance, and it did so on the basis of promising Phase III clinical trial findings from two studies (OAKS and DERBY) that showed it slowed the growth of GA lesions when compared to a placebo.
With a dosing schedule of every 25 to 60 days, pegcetacoplan injection is now authorized for use in patients with GA, whether or not subfoveal involvement is present. Pegcetacoplan is made to provide complete management of the complement cascade by focusing on C3.
Data revealed that when DERBY patients received monthly therapy, the lesion growth could be reduced by up to 36%, between months 18 and 24.
The trial's findings also pointed to a well-established safety profile after roughly 12,000 doses. The findings show that ocular discomfort, neovascular AMD, vitreous floaters, and conjunctival haemorrhage were the most frequently mentioned adverse reactions in patients getting pegcetacoplan injection.
SYFOVRE is anticipated to be accessible at the start of March 2023. The European Medicines Agency (EMA) is reviewing a marketing authorization application (MAA), and a regulatory ruling is anticipated in early 2024.
The growth of lesions that kill the retinal cells necessary for vision is a characteristic of GA, an advanced form of AMD. This primary cause of cataracts affects five million individuals worldwide and more than a million people in the United States.
It can be very difficult to carry out everyday tasks due to the disease, and it may only take two and a half years for GA lesions to start affecting the fovea.
